Target-user preferences, motivations, and acceptance for a dialectical behaviour therapy smartphone application for eating disorders
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · 2024
DOI: 10.1007/s40519-024-01646-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2024. Verfasst von Cleo Anderson und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychology, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia. ceand@deakin.edu.au. Hauptthemen laut MEDLINE: Dialectical Behavior Therapy, Mobile Applications, Feeding and Eating Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Deakin University.
Abstract (Originalsprache)
Purpose
Evidence shows that dialectical behavioural therapy (DBT) is efficacious for eating disorders (ED), yet few people have access to specialized treatments like DBT. Translating key DBT skills for delivery via a smartphone application may broaden the dissemination of evidence-based interventions. However, prior to developing a DBT-based app, it is crucial to gather information on target-user needs and preferences. Assessing overall acceptance and identifying predictors of acceptance, informed by the UTAUT framework, is also important. This process ensures not only a demand for such an app, but also that users receive content and features tailored to their needs.
Method
This study aimed to understand target-user preferences of DBT-based apps for EDs by assessing willingness to engage, overall acceptance levels, and preferred functionality/content delivery modes ( n = 326 symptomatic participants).
Results
Eighty-eight percent indicated they would be willing to use a DBT-based ED app if it were available. Acceptance levels of a DBT app were high (64%), which was uniquely predicted by performance expectancy (perceptions of how beneficial an intervention is) and facilitating conditions (expectations of technological infrastructure and support in interventions) in path analysis. Content perceived as important to contain were emotion regulation techniques, tailored intervention strategies, and psychoeducation.
Conclusion
Findings generate important information about target-user preferences of a DBT-based app for EDs, highlighting necessary design principles for apps of this kind. Level of evidence Level V, cross-sectional descriptive study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Psychology, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia. ceand@deakin.edu.au.
- Center for Social and Emotional Development, Deakin University, Burwood, VIC, 3125, Australia.
- School of Psychology, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia.
Förderung
- National Health and Medical Research Council
- Deakin University
Zitieren
APA
Anderson, C., Fuller-Tyszkiewicz, M., Messer, M., & Linardon, J. (2024). Target-user preferences, motivations, and acceptance for a dialectical behaviour therapy smartphone application for eating disorders. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. https://doi.org/10.1007/s40519-024-01646-8
Vancouver
Anderson C, Fuller-Tyszkiewicz M, Messer M, Linardon J. Target-user preferences, motivations, and acceptance for a dialectical behaviour therapy smartphone application for eating disorders. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2024. doi:10.1007/s40519-024-01646-8
BibTeX
@article{Anderson2024,
author = {Anderson, Cleo and Fuller-Tyszkiewicz, Matthew and Messer, Mariel and Linardon, Jake},
title = {Target-user preferences, motivations, and acceptance for a dialectical behaviour therapy smartphone application for eating disorders},
journal = {Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity},
year = {2024},
doi = {10.1007/s40519-024-01646-8}
}
EUVIMED